Brokerages Set Compugen Ltd. (NASDAQ:CGEN) Target Price at $5.00

Compugen Ltd. (NASDAQ:CGEN) has earned a consensus recommendation of “Buy” from the five brokerages that are currently covering the stock, MarketBeat Ratings reports. One equities research analyst has rated the stock with a hold rating, three have issued a buy rating and one has given a strong buy rating to the company. The average 1-year target price among brokerages that have updated their coverage on the stock in the last year is $5.00.

CGEN has been the topic of several recent research reports. Wall Street Zen lowered shares of Compugen from a “buy” rating to a “hold” rating in a research report on Saturday, May 23rd. Weiss Ratings raised shares of Compugen from a “sell (d-)” rating to a “hold (c-)” rating in a research report on Wednesday, August 5th. HC Wainwright restated a “buy” rating on shares of Compugen in a research note on Tuesday, August 4th. Finally, Leerink Partners cut their price target on shares of Compugen from $13.00 to $5.00 and set an “outperform” rating on the stock in a report on Thursday, May 21st.

Hedge Funds Weigh In On Compugen

Several hedge funds have recently bought and sold shares of CGEN. Bank Hapoalim BM bought a new position in Compugen during the fourth quarter valued at about $37,000. Security National Bank of Sioux City Iowa IA acquired a new position in shares of Compugen during the 4th quarter valued at about $38,000. Franklin Resources Inc. bought a new position in shares of Compugen in the 2nd quarter valued at approximately $56,000. Calamos Advisors LLC acquired a new stake in Compugen in the 1st quarter worth approximately $63,000. Finally, Hillsdale Investment Management Inc. bought a new stake in Compugen during the first quarter worth approximately $68,000. 12.22% of the stock is owned by institutional investors and hedge funds.

Compugen Price Performance

Shares of NASDAQ CGEN opened at $2.63 on Friday. Compugen has a one year low of $1.29 and a one year high of $3.23. The business’s 50-day moving average price is $2.40 and its two-hundred day moving average price is $2.36. The company has a market capitalization of $248.67 million, a P/E ratio of 6.92 and a beta of 2.78.

Compugen (NASDAQ:CGEN) last posted its quarterly earnings results on Monday, August 3rd. The biotechnology company reported ($0.07) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.08) by $0.01. The company had revenue of $2.60 million during the quarter, compared to the consensus estimate of $1.28 million. Compugen had a return on equity of 42.57% and a net margin of 47.56%.During the same period last year, the business earned ($0.08) EPS. On average, equities analysts anticipate that Compugen will post -0.27 EPS for the current year.

Compugen Company Profile

Compugen Ltd. (NASDAQ: CGEN) is a clinical-stage therapeutic discovery company that leverages proprietary computational discovery platforms to identify novel immuno-oncology targets and biomarkers. The company combines large-scale biological datasets with machine learning algorithms to generate and validate new therapeutic and diagnostic candidates. Founded in 1993 and headquartered in Tel Aviv, Israel, Compugen also maintains a presence in the United States to support its clinical development and commercial collaborations.

Compugen’s predictive discovery engine scans complex biological systems in silico to reveal previously unrecognized pathways and immune checkpoints involved in cancer progression.